RxDoctor Payments Data

Ellen Young, PA

Physician Assistant · Easley, SCNPI 1205161957

Payments from drug & device makers

$9,007in general payments, 2019–2025

Across 626 payments — averaging $14.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$873
  • Novo Nordisk$862
  • AstraZeneca$689
  • Amgen$516
  • Pfizer$506
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$8,90899%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,007 in reported general payments places this provider in the 95th percentile of 1,852 physician assistant providers in South Carolina.

See all physician assistant providers in South Carolina

Medicare billing

Part B allowed, 2024
$4,370
Medicare patients
32
Services billed
65

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide53$58,196
OzempicSemaglutide28$47,768
XareltoRivaroxaban43$39,024
JardianceEmpagliflozin22$31,011
Repatha SureclickEvolocumab38$28,198
FarxigaDapagliflozin Propanediol17$17,374
EliquisApixaban19$10,639
Synjardy XrEmpagliflozin/Metformin Hcl15$8,920
KerendiaFinerenone11$8,619
TrintellixVortioxetine Hydrobromide12$5,740
SynthroidLevothyroxine Sodium35$2,894
Duloxetine Hcl87$2,787
Omeprazole192$2,413
Rosuvastatin Calcium198$2,020
Clorazepate Dipotassium29$1,449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$873$58,19653 claims
Novo NordiskOzempic$862$47,76828 claims
Boehringer IngelheimJardiance, Synjardy Xr$90$39,93137 claims
Johnson & JohnsonXarelto$52$39,02443 claims
AstraZenecaFarxiga$689$17,37417 claims
PfizerEliquis$506$10,63919 claims
BayerKerendia$396$8,61911 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$298$5,74012 claims
AbbVieSynthroid$1,394$2,89435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,852 physician assistant providers in South Carolina.

Other physician assistant in Easley

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →